Post My Press Release

Free Press Release Distribution

Category: Pharmaceutical Industry (Page 1 of 52)

Tubular Membranes Market – Size, Share and Forecast ,2019-2026

Market Overview:

The Tubular Membranes market size was worth USD YY million in 2018 and is estimated to reach USD YY million by 2026, at a CAGR of YY% during the forecast period.

Tubular membranes are not self-supporting membranes. They are located on the inside of a tube, made of a special kind of material. This material is the supporting layer for the membrane. Because the location of tubular membranes is inside a tube, the flow in a tubular membrane is usually inside out. The main cause for this is that the attachment of the membrane to the supporting layer is very weak

Market Dynamics:

Increasing guidelines and regulations on wastewater discharge and rising technological advancements, and rising importance on decreasing the capital and operating costs of ZLD systems using membranes are the major drivers impacting the market growth. Environmental regulations create a demand for companies to cut effluent volumes, economics also plays a major role for the market growth.

Segment Analysis:

By end user, the tubular membranes market is segmented into:

  • Food & beverages
  • Chemicals & petrochemicals
  • Pharmaceuticals
  • Power & energy
  • Electrophoretic coating
  • Leathers & textiles
  • Others

In the food industry there is an increasing awareness that tubular membrane systems can be easily integrated into an existing process line and provide a useful concentrate and a valuable filtrate or permeate at the same time

By application, the tubular membranes market is segmented into

  • Reverse osmosis
  • Membrane bioreactors
  • Other applications

Reverse osmosis is a key segment for the tubular membranes market. Reverse osmosis (RO) is a water purification process that uses a partially permeable membrane to remove ions, unwanted molecules and larger particles from drinking water.

Geographical Analysis:

By geography, the Tubular membrane market is segmented into:

  • North America
  • Asia-Pacific (APAC)
  • Europe
  • South AmericaMiddle East and Africa (MEA)

North America is dominating the Tubular Membranes market in 2018 and estimated to hold largest market size over the forecast period owing to the rising regulations on end-use industries towards wastewater discharge, causing in the demand for ZLD systems and ultimately tubular membranes.

Competitive Landscape:

The Tubular Membranes market is a competitive with existing players in the market.

Key players include:

  • Berghof Membrane Technology GmbH
  • Porex Corporation
  • Hyflux Ltd
  • PCI Membranes
  • Others

View full sample report: https://www.datamintelligence.com/research-report/tubular-membranes-market

Download free sample: https://www.datamintelligence.com/download-sample/tubular-membranes-market

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1-888-702-9626

Website: www.datamintelligence.com

Global Hepatic Encephalopathy Drugs Market Analysis Revealing Key Drivers & Growth Trends through 2025

The purpose of this research report titled “Global Hepatic Encephalopathy Drugs Market Insights, Forecast to 2025” is to enlighten the readers about the global market during the period between 2019 and 2025. Market Research Hub (MRH) has diligently compiled this study to discuss various facets of the global Hepatic Encephalopathy Drugs market together with the various players contributing to its future development. The inclusion of market dynamics, market size, revenue share, forecast growth etc., makes this assessment a rich data source for investors, shareholders and new entrants.

Get an Exclusive Sample of this Report@ – https://www.marketresearchhub.com/enquiry.php?type=S&repid=2349976   

Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with cirrhosis and variceal bleeding. Lactulose, is considered the first-line therapeutic agent for treating hepatic encephalopathy. Based on route of administration, Hepatic Encephalopathy Drugs include oral (tablets & solutions) and injections.
The global Hepatic Encephalopathy Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hepatic Encephalopathy Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Hepatic Encephalopathy Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hepatic Encephalopathy Drugs in these regions.
This research report categorizes the global Hepatic Encephalopathy Drugs market by top players/brands, region, type and end user. This report also studies the global Hepatic Encephalopathy Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
ASKA Pharmaceutical
Cosmo Pharmaceuticals
Bausch Health
Ferring Pharmaceuticals
Mallinckrodt
Umecrine Cognition
Norgine
Lupin
Kaleido Biosciences
Kannalife Sciences

Hepatic Encephalopathy Drugs market size by Type
Injection
Oral
Hepatic Encephalopathy Drugs market size by Applications
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
Turkey
GCC Countries
Egypt
South Africa

In this study, the years considered to estimate the market size of Hepatic Encephalopathy Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hepatic Encephalopathy Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Detailed Analysis of this Research Report@ – https://www.marketresearchhub.com/report/global-hepatic-encephalopathy-drugs-market-insights-forecast-to-2025-report.html

Table of Contents
1 Study Coverage
1.1 Hepatic Encephalopathy Drugs Product Introduction
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type
1.4.2 Injection
1.4.3 Oral
1.5 Market by Application
1.5.1 Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Hepatic Encephalopathy Drugs Market Size
2.1.1 Global Hepatic Encephalopathy Drugs Revenue 2014-2025
2.1.2 Global Hepatic Encephalopathy Drugs Sales 2014-2025
2.2 Hepatic Encephalopathy Drugs Growth Rate by Regions
2.2.1 Global Hepatic Encephalopathy Drugs Sales by Regions
2.2.2 Global Hepatic Encephalopathy Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Hepatic Encephalopathy Drugs Sales by Manufacturers
3.1.1 Hepatic Encephalopathy Drugs Sales by Manufacturers
3.1.2 Hepatic Encephalopathy Drugs Sales Market Share by Manufacturers
3.2 Hepatic Encephalopathy Drugs Revenue by Manufacturers
3.2.1 Hepatic Encephalopathy Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Hepatic Encephalopathy Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Hepatic Encephalopathy Drugs Price by Manufacturers
3.4 Hepatic Encephalopathy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hepatic Encephalopathy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hepatic Encephalopathy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hepatic Encephalopathy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

TOC continued…!

Enquire before purchase@ – https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2349976

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us         

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Read Industry News at: https://www.industrynewsanalysis.com/

Duchenne Muscular Dystrophy Market Insights, Forecast 2019-2026

Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.

Key players in the market include Bristol-Myers Squibb Company, FibroGen, Inc., ITALFARMACO S.p.A., Marathon Pharmaceuticals, LLC, NS Pharma, Inc, PTC Therapeutics, Inc., Pfizer Inc., ReveraGen BioPharma, Inc., Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.

Download Sample PDF Brochure at: https://www.alliedmarketresearch.com/request-toc-and-sample/4102

Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, low rate of treatment due to delayed diagnosis and prediction hinder the market growth. Moreover, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.

The global Duchenne muscular dystrophy therapeutics market is segmented on the basis of type, end user, and region. On the basis of type, it is bifurcated into pain management drugs and corticosteroids. Corticosteroids are further sub-segmented into prednisolone, prednisone, and deflazacort. On the basis of end-user, it is divided into hospitals, clinics, and home care settings. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by product helps understand various therapeutics used for Duchenne dystrophy.
  • Comprehensive analysis of all geographical regions is provided, which helps determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market.

Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4102

HIV Diagnosis Market

Global HIV Diagnosis Market – Industry Trends and Forecast to 2021

According to a new market research report “HIV Diagnosis Marketby Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification), Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) – Global Forecast to 2021″ published by MarketsandMarkets, the market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021.

The report provides a detailed overview of the major drivers, restraints, opportunities, trends, and strategies impacting the HIV diagnosis market along with the estimates and forecasts of the revenue and market share analysis. The major factors driving the growth of this market are increasing prevalence of HIV/AIDS worldwide, increasing number of blood transfusions and blood donations, advancements and benefits offered by point-of-care instruments & kits, and increasing awareness about HIV/AIDS and increasing government initiatives.

The report segments this market based on product, test type, end user, and region. On the basis of product, the market is segmented into consumables (assay, kits, reagents, and other consumables), instruments, and software and services. In 2016, the consumables segment is expected to account for the largest share of the market. The frequent and repetitive purchase of consumables by laboratories and hospitals, growing prevalence of HIV/AIDS, and increasing initiatives from governments to fight HIV/AIDS are some of the major factors driving the consumables market.

View Press Release – https://www.marketsandmarkets.com/PressReleases/hiv-diagnosis.asp

On the basis of end user, the HIV diagnosis market is segmented into diagnostic laboratories, hospitals, blood banks, home care settings, and others (gene banks, cell banks, biotechnology and pharmaceutical companies, and academic research institutes). The diagnostic laboratories segment is expected to account for the largest share of HIV diagnosis market in 2016. Increasing awareness about HIV/AIDS and advancements in PoC instruments and consumables are major drivers for this end-user segment.

On the basis of region, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2016, North America is expected to account for the largest share of the market. Growth in this region is mainly driven by the high prevalence of HIV/AIDS, increasing number of blood transfusion and blood donations, increasing awareness about HIV/AIDS and increasing government initiatives, and technological advancements test and better offering of PoC settings.

Key players in the HIV Diagnosis Market include Siemens AG (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S), Danaher Corporation (U.S.), Thermo-Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Becton, Dickinson and Company (U.S.), Hologic, Inc. (U.S.), Alere Inc. (U.S.), and Bio-Rad Laboratories (U.S.).

Know more about key industry players – https://www.marketsandmarkets.com/ResearchInsight/hiv-diagnosis-market.asp

Latest Research on Environmental Monitoring Market Expected to Hits $25.5 Billion by 2024

Environmental Monitoring Market is projected to reach USD 25.5 billion by 2024 from USD 18.4 billion in 2019, at a CAGR of 6.8% during the forecast period.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=216846315

Environmental Monitoring Market

Top Key Players

Agilent Technologies (US), Danaher Corporation (US), ThermoFisher Scientific (US), Shimadzu Corp. (Japan), and PerkinElmer Corporation (US). The other players are General Electric (US), Honeywell International Inc (US), Horiba (Japan), Merck KGaA (Germany), Siemens (Germany), Teledyne Technologies Incorporated (US), Emerson Electric (US), Spectris (UK), TE Connectivity (US), and 3M Company (US) among others are some major players in the global Environmental Monitoring Market.

Browse in-depth TOC onEnvironmental Monitoring Market

187 — Tables

56 — Figures

248 — Pages

Rising pollution levels, favourable regulatory scenario, ongoing installation of environmental monitoring stations, development of environment-friendly industries, increasing awareness on pollution monitoring, expansion of pollution monitoring infrastructure across emerging markets, are the major factors driving the growth of the global environmental monitoring market.

North America accounted for the largest share of the Environmental Monitoring Market in 2018. The dominant position of this region is due to an increase in government funding for the establishment of environmental monitoring stations and the US EPA’s stringent regulations that supports greater adoption of pollution monitoring technologies. 

Additionally, technological advancements in the field of environmental sensors and growing government initiatives in the area of pollution control will further augment market growth.

Read More @ https://www.marketsandmarkets.com/PressReleases/environmental-monitoring.asp

Systemic Lupus Erythematosus Market Advanced Technology, Future Opportunities And Forecast Till 2025 : Grand View Research Inc.

San Francisco, 10 July 2019: The Report Systemic Lupus Erythematosus Market Size, Share & Trends Analysis Report by Drug Class (Immunosuppressants, Biologics, Antimalarials, NSAIDs, Corticosteroids), By Route of Administration, and Segment Forecasts 2018 – 2025

The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. Certain new promising drugs that are currently in Phase III trials are anticipated to augment the market as these drugs may target the lupus nephritis patient subset with few effective alternatives and significant unmet needs to be met. This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.

Use of approved biologic, Benlysta, through clinical studies, has revealed drastic improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s current initiatives center on further increasing opportunities for Benlysta. The company is conducting indication expansion clinical trials, combination therapy studies with rituximab, and new product development, to widen opportunities for its therapy. In this direction, recent launch of Benlysta’s subcutaneous formulation in several countries is expected to boost the SLE market over the forecast period.

Access Research Report of Systemic Lupus Erythematosus Market @ www.grandviewresearch.com/industry-analysis/systemic-lupus-erythematosus-sle-market

Further key findings from the study suggest:

  • North America was the major contributor for the SLE market revenue in 2017 and is anticipated to rise at a CAGR of 8.1% during the forecast period. This is due to availability of reimbursement and better healthcare infrastructure and accessibility to biologics.
  • Europe was ranked as the second largest regional market in the SLE market in 2017 and is expected to register a CAGR of 5.5% over the forecast period
  • Immunosuppressants held the largest share in the market in 2017 due to their low cost and high accessibility, whereas the biologics segment is projected to post the highest CAGR during the same period
  • In 2017, the oral segment held the dominant share of over 54.0% in the market, followed by the intravenous segment that requires trained medical personnel for administration. Over the forecast years, the latter is poised to expand at a CAGR of 10.4%
  • Key players in this space include GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer, and Sanofi. By 2025, other companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are anticipated to enter the SLE market.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global systemic lupus erythematosus market by drug class, route of administration, and region:

Systemic Lupus Erythematosus Drug Classes Outlook (Revenue, USD Million, 2014 – 2025)

  • NSAIDs
  • Corticosteroids
  • Antimalarials
  • Immunosuppressants
  • Biologics

Systemic Lupus Erythematosus Route of Administration Outlook (Revenue, USD Million, 2014 – 2025)

  • Oral
  • Intravenous
  • Subcutaneous

Systemic Lupus Erythematosus Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Access Press Release of Systemic Lupus Erythematosus Market @ www.grandviewresearch.com/press-release/global-systemic-lupus-erythematosus-sle-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Biosimilars Market Is Expected To Reach Over USD 61.47 Billion By 2025 : Grand View Research Inc.

San Francisco, 23 July 2019: The Report Biosimilars Market Size, Share & Trends Analysis Report By Product, By Application (Oncology, Growth Hormone, Blood Disorders, Chronic & Autoimmune Disorders), By Region, And Segment Forecasts, 2018 – 2025

The global biosimilars market size is expected to reach a value of USD 61.47 billion by 2025, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 34.2% over the forecast period. Major biological drugs are approaching the patent cliff. This is the most significant driving factor for the market. For instance, Roche’s MabThera/Rituxan (rituximab), a monoclonal antibody biologics was approved by the U.S. Food and Drug Administration (FDA) in November 1997 and its U.S. patent expired in September 2016. Several companies such as Amgen, Boehringer Ingelheim, and Pfizer are focusing on development of biosimilar drug of rituximab.

Furthermore, lower cost of biosimilars compared to patented biologics and positive outcomes in clinical trials are expected to boost market growth. For instance, in July 2016; Allergan plc and Amgen stated results from a Phase 3 clinical study of ABP 980 compared with trastuzumab, a recombinant DNA-derived humanized monoclonal antibody. This drug was approved for early and metastatic breast cancer and metastatic gastric cancer in many regions. Currently, there is a boom in pharmaceutical industry for the development of biosimilar drugs, which is a cost-saving alternative to biologic drugs. Amgen Inc.; Sandoz International GmbH; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Biocon; Samsung Bioepis; and Mylan N.V are some of the companies focusing on the development and production of biosimilars.

Access Research Report of Biosimilars Market @ www.grandviewresearch.com/industry-analysis/biosimilars-market

Further key findings from the report suggest:

  • In 2016, recombinant non-glycosylated protein was the largest revenue-grossing segment in the biosimilars market owing to prevalence of growth hormone deficiency and diabetes and other chronic diseases
  • Recombinant glycosylated protein segment is expected to grow at significant rate during the forecast period owing to demand for erythropoietin and monoclonal antibodies for treatment of cancer and anemia
  • Oncology accounted for the largest share in application segment in 2016 due to increasing adoption of low cost biosimilar drugs for cancer treatment
  • Europe was the leading regional segment in terms of revenue share in 2016 owing to favorable regulatory policies
  • North America is expected to witness the highest CAGR during the forecast period owing to high prevalence of chronic diseases and rising number of drug approvals
  • Some of the major players are Amgen Inc.; F. Hoffmann-La Roche Ltd.; Sandoz International GmbH; Dr. Reddy’s Laboratories Ltd.; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Samsung Bioepis; Biocon; and Mylan N.V.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global biosimilars market on the basis of product, application, and region:

Biosimilars Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Recombinant Non-glycosylated Proteins
    • Human Growth Hormones
    • Granulocyte Colony-stimulating Factor (G-CSF)
    • Interferons
    • Insulin
  • Recombinant Glycosylated Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin

Biosimilars Application Outlook (Revenue, USD Million, 2014 – 2025)

  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others

Biosimilars Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
  • Europe
  • Asia Pacific
  • RoW

Access Press Release of Biosimilars Market @ www.grandviewresearch.com/press-release/global-biosimilars-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Electrodeionization Market worth 1,124 Million USD by 2024, registering a CAGR of 6.3%

The report “Electrodeionization Market by Design (Plate and Frame Construction, and Spiral Wound Construction), End-use Industry (Power Generation, Pharmaceuticals, Electronics & Semiconductor), and Region – Global Forecast to 2024” The electrodeionization market in 2019 is estimated to be USD 827 million and is projected to reach USD 1,124 million by 2024, at a CAGR of 6.3% from 2019 to 2024. This growth is mainly attributed to the increasing demand for ultrapure water from varied end-use industries such as power generation, pharmaceuticals, electronics & semiconductor and among others.

Request PDF brochure of report for more details: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=254938571

Browse 70 market data Tables and 33 Figures spread through 108 Pages and in-depth TOC on “Electrodeionization Market“

Power Generation end-use industry segment accounts for the largest share of the electrodeionization market

The power generation end-use industry segment is estimated to account for the largest share of the electrodeionization market in 2019. Electrodeionization plays an important role in the power generation industry, which produces ultrapure water to enable high pressure and smooth functioning of turbines. Ultrapure water avoids clotting or disruption in boiler tubes as well as high temperature corrosion. The recognition of the enhanced effect of ultrapure water for power generation has led to an increase in the demand for electrodeionization in the power generation industry

On the basis of Design, Plate and Frame construction segment is projected to lead the electrodeionization market by 2024

The Plate and Frame construction design is expected to account for the largest share of electrodeionization market in 2019. EDI systems with such designs operate under the co-flow configuration, in which, the direction of flow in the concentrate chamber is the same as in the diluting chamber. The product compartments are identical to each other, as are the reject compartments, due to which, the plate & frame design offers the advantage of equal water flow and electric current distribution among the stacks. This design has lower operating cost, simple design and high durability, due to which, the demand for plate & frame construction is expected to grow during the forecast period.

The Asia-Pacific region is expected to lead the electrodeionization market during the forecast period

The Asia-Pacific region is estimated to account for the largest share of the electrodeionization market in 2019 followed by North America and Europe. China is one of the major consumers of electrodeionization in the Asia-Pacific region. Availability of cheap labor and increasing foreign direct investments in the power generation, pharmaceuticals and electronics & semiconductor industries in the Asia-Pacific region are anticipated to drive the demand for electrodeionization.

Major manufacturers operated in this report include Suez SA (France), Veolia Environnement S.A. (France), Evoqua Water Technologies LLC (US), Qua Group (US), DowDuPont Inc. (US), Snowpure LLC (US), Mega a.s. (Czech Republic), Ovivo Inc. (Canada), Pure Aqua Inc. (USA) and among others

Early buyers will receive 10% customization on this report.

Don’t miss out on business opportunities in Electrodeionization Market.

Read our blog for more details:  https://chemabd007.blogspot.com/2019/07/electrodeionization-market-anticipated.html

About MarketsandMarkets

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA: 1-888-600-6441 
sales@marketsandmarkets.com

Page 1 of 52

Powered by WordPress & Theme by Anders Norén